The synthesis of a benzoic acid half mustard 3 was achieved in high yield using a reductive-alkylation approach. This method can be scaled up (in this case 10g) and it is adaptable to the synthesis of other half mustards.
The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH
2
—; E represents a nitrogen-containing non-aromatic heterocycle; R
1
represents an alkoxy group or the like; R
2
represents a hydrogen atom or the like; and R
3
represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R
2
or R
3
is present on a nitrogen atom on the azetidine ring, the R
2
or R
3
does not represent a hydrogen atom.
In current research, five series of mono- and di-substituted piperazinederivatives have been synthesized. For di-substituted derivatives, ciprofloxacin was selected and hybrids were synthesized via substitution at piperazinyl-N4. In vitro antibacterial studies of all synthesized compound were carried out against American Type Culture Collection (ATCC) strains; E. coli (ATCC 25922), P. aeruginosa (ATCC